

THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular or as to the action you should take, you should consult your stockbroker or other registered dealer in securities, bank manager, solicitor, professional accountant or other professional adviser.

If you have sold or transferred all your shares in China Isotope & Radiation Corporation, you should at once hand this circular and the accompanying proxy form to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.

**CHINA ISOTOPE & RADIATION CORPORATION****中國同輻股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

**CONNECTED TRANSACTION
AND
DISCLOSEABLE TRANSACTION
PROPOSED APPOINTMENT OF DIRECTOR
PROPOSED INTERIM DIVIDEND
AND
PROPOSED GRANT OF GENERAL MANDATE TO ISSUE SHARES**

**Independent Financial Adviser
to the Independent Board Committee
and the Independent Shareholders**



RAINBOW CAPITAL (HK) LIMITED
滄博資本有限公司

A letter from the Board is set out on pages 5 to 26 of this circular. Capitalised terms used on this cover page have the same meanings as defined in this circular.

The Company will convene the EGM at 10:00 a.m. on Wednesday, 21 October 2026 at Room 403, 4/F, No. 66 Changwa Middle Street, Haidian District, Beijing, China. Notice of the EGM is set out on pages EGM-1 to EGM-2 of this circular. The proxy form for the EGM is enclosed herewith.

Shareholders who intend to appoint a proxy to attend the EGM are requested to complete the relevant proxy form in accordance with the instructions printed thereon. The relevant proxy form shall be lodged with (in respect of holders of H Shares) the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, or (in respect of holders of Domestic Shares) the Company's head office and principal place of business in the PRC at No. 66 Changwa Middle Street, Haidian District, Beijing, China, as soon as possible and in any event not less than 24 hours before the time appointed for the holding of the EGM (i.e. 10:00 a.m. on Tuesday, 20 October 2026) or any adjourned meeting thereof (as the case may be), respectively. Completion and return of the relevant proxy form will not prevent you from attending and voting in person at the EGM or any adjourned meeting thereof should you so wish.

29 September 2026

CONTENTS

	<i>page</i>
Definitions	1
Letter from the Board	5
1. Introduction	5
2. Connected Transaction and Discloseable Transaction	6
3. Proposed Appointment of Director	21
4. Proposed Interim Dividend	23
5. Proposed Grant of General Mandate to Issue Shares	24
6. EGM	25
7. Voting by Poll	26
8. Recommendation	26
Letter from the Independent Board Committee	27
Letter from the Independent Financial Adviser	29
Appendix I – General Information	I-1
Appendix II – Shareholding and Relationship Chart of the Fund	II-1
Notice of Extraordinary General Meeting	EGM-1

DEFINITIONS

In this circular, unless the context otherwise requires, the following expressions have the following meanings:

“Articles of Association”	The articles of association of the Company, as amended from time to time
“associate(s)”	has the meaning ascribed thereto under the Listing Rules
“Board”	the board of directors of the Company
“CIAE”	China Institute of Atomic Energy
“CNNC”	China National Nuclear Corporation (中國核工業集團有限公司, previously known as “中國核工業集團公司”), a company established under the laws of the PRC on 29 June 1999, the controlling Shareholder of the Company
“CNNC 404”	CNNC 404 Company Limited
“CNNC Capital”	CNNC Capital Holdings Limited (中國核工業集團資本控股有限公司)
“CNNC Fund”	CNNC Industrial Fund Management Co., Ltd.(中核產業基金管理有限公司)
“Company”	China Isotope & Radiation Corporation
“Company Law”	the Company Law of the PRC
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	director(s) of the Company
“Domestic Share(s)”	domestic share(s) in the share capital of the Company with a nominal value of RMB1.00 each, which are subscribed for or credited as paid in RMB
“EGM”	the extraordinary general meeting of the Company to be held at 10:00 a.m. on Wednesday, 21 October 2026 at Room 403, No. 66 Changwa Middle Street, Haidian District, Beijing, China

DEFINITIONS

“Fund”	CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership (Limited Partnership) (中核(浙江)核技術應用產業投資基金合夥企業(有限合夥)) (tentative name, subject to the final approval of the company registration authority), proposed to be established pursuant to the Partnership Agreement
“Group”	the Company and its subsidiaries
“H Share(s)”	overseas listed foreign share(s) in the share capital of the Company with a nominal value of RMB1.00 each which are subscribed for and traded in HK\$ and listed on The Stock Exchange of Hong Kong Limited
“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Haiyan County State-owned Assets Investment”	Haiyan County State-owned Assets Investment Co., Ltd. (海鹽縣國有資本投資有限公司)
“Hong Kong”	Hong Kong Special Administrative Region of the PRC
“Independent Board Committee”	the independent board committee of the Board, comprising Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui, all being the independent non-executive Directors of the Company
“Independent Financial Adviser” or “Rainbow Capital”	Rainbow Capital (HK) Limited
“Independent Third Party(ies)”	independent third party(ies) who is/are not connected person(s) of the Company and its subsidiaries, and is/are independent of the Company and its connected person(s) (as defined in the Listing Rules)
“Jiaxing Changchuang Industrial Investment”	Jiaxing Changchuang Industrial Investment Equity Investment Partnership (Limited Partnership) (嘉興長創產投股權投資合夥企業(有限合夥))
“Latest Practicable Date”	25 September 2026, being the latest practicable date prior to the printing of this circular for the purpose of ascertaining certain information contained herein

DEFINITIONS

“Listing Rules”	the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited
“NPIC”	Nuclear Power Institute of China
“Partnership Agreement”	the Partnership Agreement of CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership (Limited Partnership) (中核(浙江)核技術應用產業投資基金合夥企業(有限合夥)合夥協議) expected to be entered into by and among the Company, CNNC Fund, CNNC, CNNC Capital, National Industrial Investment Fund, Zhejiang Province Entrepreneurship Guide Fund, Jiaxing Changchuang Industrial Investment and Haiyan County State-owned Assets Investment in December 2026
“PBOC”	the People’s Bank of China, the central bank of the PRC
“PRC” or “China”	the People’s Republic of China, excluding, for the purpose of this circular only, Hong Kong, Macau Special Administrative Region and Taiwan
“RMB”	Renminbi, the lawful currency of the PRC
“SFO”	Securities and Futures Ordinance (Cap. 571)
“Share(s)”	the ordinary shares in the capital of the Company with a nominal value of RMB1.00 each, comprising the Domestic Shares and the H Shares
“Shareholder(s)”	shareholder(s) of the Company

DEFINITIONS

“Transactions”	The proposed total capital contributions committed by the Company, CNNC Fund, CNNC, CNNC Capital, National Industrial Investment Fund, Zhejiang Province Entrepreneurship Guide Fund, Jiaxing Changchuang Industrial Investment and Haiyan County State-owned Assets Investment to the Fund are RMB3,000 million, of which CNNC Fund proposes to commit RMB30 million (representing 1%), the Company proposes to commit RMB400 million (representing 13.33%), National Industrial Investment Fund proposes to commit RMB1,000 million (representing 33.33%), CNNC proposes to commit RMB200 million (representing 6.67%), CNNC Capital proposes to commit RMB170 million (representing 5.67%), Zhejiang Province Entrepreneurship Guide Fund proposes to commit RMB400 million (representing 13.33%), Jiaxing Changchuang Industrial Investment proposes to commit RMB400 million (representing 13.33%), and Haiyan County State-owned Assets Investment proposes to commit RMB400 million (representing 13.33%).
“Zhejiang Province Entrepreneurship Guide Fund”	Zhejiang Province Entrepreneurship Risk Investment Guide Fund Management Limited (浙江省創業風險投資引導基金管理有限公司)
“2026 Interim Results Announcement”	Announcement of Interim Results for the Six Months Ended 30 June 2026 of the Company dated 28 August 2026

LETTER FROM THE BOARD



CHINA ISOTOPE & RADIATION CORPORATION 中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

Members of the Board

Chairman and executive Director:
Mr. Xiao Yafei

Registered Office

Room 418, South 4th Floor, Building 1
No. 66 Changwa Middle Street
Haidian District
Beijing
PRC

Executive Director:
Ms. Huo Yingying

Head Office and Principal Place of Business in the PRC

No. 66 Changwa Middle Street
Haidian District
Beijing
PRC

Non-executive Directors:

Mr. Chen Zan
Mr. Ding Jianmin
Mr. Zhang Guoliang
Ms. Chang Jinyu

Principal Place of Business in Hong Kong

5/F, Manulife Place
No. 348 Kwun Tong Road
Kowloon
Hong Kong

Independent non-executive Directors:

Mr. Poon Chiu Kwok
Ms. Chen Jingshan
Mr. Lu Chuang
Mr. An Rui

To the Shareholders:

Dear Sir/Madam

**CONNECTED TRANSACTION
AND
DISCLOSEABLE TRANSACTION
PROPOSED APPOINTMENT OF DIRECTOR
PROPOSED INTERIM DIVIDEND
AND
PROPOSED GRANT OF GENERAL MANDATE TO ISSUE SHARES**

1. INTRODUCTION

The purpose of this circular, of which this letter forms a part, is to give you notice of the EGM, and to provide you with all the information reasonably necessary to enable you to make an informed decision on whether to vote for or against the proposed resolutions at the EGM.

LETTER FROM THE BOARD

At the EGM, ordinary resolutions will be proposed to consider and, if thought fit, approve, among other things: (i) the Partnership Agreement and the transactions contemplated thereunder; (ii) the proposed appointment of Mr. Li Penghui as an executive Director; and (iii) the proposed declaration and distribution of an interim dividend in the amount of RMB0.0994 per Share (inclusive of tax) for the six months ended 30 June 2026. A special resolution will be proposed at the EGM to consider and, if thought fit, approve the proposed grant of general mandate to issue Shares. Notice of the EGM is set out on pages EGM-1 to EGM-2 of this circular.

2. CONNECTED TRANSACTION AND DISCLOSEABLE TRANSACTION

The Partnership Agreement and the transactions contemplated thereunder

I. Introduction

On 28 August 2026, the Board approved the Company's entering into the Partnership Agreement with CNNC, CNNC Capital, CNNC Fund, National Industrial Investment Fund, Zhejiang Province Entrepreneurship Guide Fund, Jiaxing Changchuang Industrial Investment, Haiyan County State-owned Assets Investment.

II. Major Terms of the Partnership Agreement

Parties:	CNNC Fund (as the general partner) The Company (as the limited partner) CNNC (as the limited partner) CNNC Capital (as the limited partner) National Industrial Investment Fund (as the limited partner) Zhejiang Province Entrepreneurship Guide Fund (as the limited partner) Jiaxing Changchuang Industrial Investment (as the limited partner) Haiyan County State-owned Assets Investment (as the limited partner)
Name of partnership:	CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership (Limited Partnership)
Place of registration:	Haiyan, Jiaxing, Zhejiang Province

LETTER FROM THE BOARD

Amount of contribution:	The total capital contributions proposed to be committed by the partners are RMB3,000 million, of which CNNC Fund proposes to commit RMB30 million (representing 1%), the Company proposes to commit RMB400 million (representing 13.33%), National Industrial Investment Fund proposes to commit RMB1,000 million (representing 33.33%), CNNC proposes to commit RMB200 million (representing 6.67%), CNNC Capital proposes to commit RMB170 million (representing 5.67%), Zhejiang Province Entrepreneurship Guide Fund proposes to commit RMB400 million (representing 13.33%), Jiaxing Changchuang Industrial Investment proposes to commit RMB400 million (representing 13.33%), and Haiyan County State-owned Assets Investment proposes to commit RMB400 million (representing 13.33%). The contribution to the Fund was determined by the Parties after arm's length negotiations with reference to the capital requirements of the Fund. The Company intends to finance its capital contribution from the internal resources of the Group. The Company will not consolidate its financial statements with those of the Fund.
Method of contribution:	All partners shall make contributions to the Fund in RMB in cash in accordance with the notice of payment of contribution given by the executive partner to the limited partners. The date of receipt of funds specified in the notice of payment of the first contribution is the first closing date. All partners shall pay their subscribed capital contributions in full in two instalments during the investment period, with 40% and 60% of their respective subscribed capital contributions payable in the first and second instalments, respectively.
Liabilities of the partners for the debts of the Fund:	The general partner assumes unlimited joint and several liability for the debts of the Fund, and the limited partners are responsible for the debts of the Fund to the extent of the amount of capital contribution committed by them.
Purpose and scope of investment:	Engaging in investment activities, primarily through the acquisition, holding and disposal of interests in investment portfolios, to generate investment returns for the partners.

LETTER FROM THE BOARD

The Fund will invest in the application areas of nuclear technology, including the production and preparation of isotope, nuclear medical equipment and innovative drugs, industrial irradiation and inspection, security inspection and protection, as well as related applications and key upstream and downstream segments of nuclear technology in the industrial, agricultural, medical, environmental protection and security fields.

Investment strategy and target sectors

100% of the Fund's investments shall be made in the nuclear technology application sector, including the production and preparation of isotopes, nuclear medical equipment and innovative pharmaceuticals, industrial irradiation and inspection, security screening and protection, as well as relevant applications of nuclear technology in the industrial, agricultural, medical, environmental protection and safety sectors, together with key upstream and downstream links.

Specifically, the Fund intends to focus primarily on the following three investment tracks:

Investment track	Principal investment focus
Isotope production and preparation	Isotope production reactors, accelerator-based isotope production, extraction from spent fuel and large-scale production of stable isotopes, with a focus on securing scarce upstream production capacity and strengthening domestic isotope supply
Nuclear medical and high-end equipment	Innovative radiopharmaceuticals, large-scale nuclear medical equipment, high-end irradiation equipment, security inspection equipment and radiation monitoring equipment, with a focus on technological innovation, domestic substitution and commercialization
Key components and upstream materials	Key components, critical upstream materials and other technologies relevant to nuclear technology applications and emerging industries, with a focus on addressing technological bottlenecks and capturing valuation upside from technological breakthroughs

LETTER FROM THE BOARD

	The Fund's investment strategy is to identify enterprises and projects in the above sectors with technological competitiveness, commercialisation potential and growth prospects and make investments therein, thereby generating investment returns.
Investment targets selection criteria	The Fund intends to invest principally in mature-stage and growth-stage projects, while allocating a relatively smaller portion of its capital to seed-stage projects. For mature-stage projects, the Fund will generally prioritise established nuclear technology application enterprises with validated business models, stable management and technical teams, established customer bases and revenue streams, positive or near-positive cash flow, competitive positions in their respective market segments and identifiable exit prospects, including the potential for an IPO or industrial acquisition within approximately three to five years. For growth-stage projects, the Fund will primarily focus on sectors with relatively clear growth prospects, including innovative radiopharmaceuticals, nuclear medical equipment and irradiation applications. Target companies would generally be expected to have products that have reached the clinical, pilot production or more advanced stages, or have otherwise achieved commercial validation; possess proprietary intellectual property or identifiable technological barriers; have management teams with both research and development capability and commercial experience; demonstrate a clear path to profitability; and possess differentiated competitive advantages and the potential to become leading participants in their respective market segments. For seed-stage projects, the Fund will selectively invest in commercialisable technological achievements originating from national research institutes and research institutes affiliated with central state-owned enterprises, particularly technologies which may address strategically important technological bottlenecks in the nuclear technology application industry. Such investments are intended to provide long-term capital support for the commercialisation of original and potentially disruptive technologies.

LETTER FROM THE BOARD

Deployment plan	The Fund has an investment period of four years from the first closing date. The partners are expected to contribute their respective capital commitments in two instalments of 40% and 60%. Other than the first instalment, CNNC Fund may generally initiate the subsequent capital call only after 80% of the preceding contribution has been utilised or reserved for investments approved by the investment committee, Fund expenses or other permitted purposes. Accordingly, capital will be deployed progressively by reference to the actual progress of suitable investments. During the investment period, the Fund is expected to deploy capital substantially in accordance with the three-track allocation and to maintain a diversified portfolio across different stages of development, with mature-stage and growth-stage investments forming the principal part of the portfolio and seed-stage projects accounting for a relatively limited portion.
Business scope:	Engaging in activities including equity investment, investment management and asset management through private equity funds (business activities can only be conducted after completing registration and filing with the Asset Management Association of China) (except for projects subject to approval according to law, business activities shall be carried out independently according to the business license) (subject to the business scope as finally approved by the company registration authority).
Term of operation:	Long-term, starting from the date of issuance of the first business licence of the Fund.
Valid duration, investment period, exit period and extension period:	The “valid duration” is eight (8) years from the first closing day; The “investment period” is four (4) years from the first closing day; The “exit period” commences on the day after the expiry of the investment period and ends on the expiry date of the valid duration;

LETTER FROM THE BOARD

Subject to the operational needs of the Fund, the valid duration may be extended with the consent of partners holding more than two-thirds of the partnership interests (calculated based on the proportion of paid-in capital contributions) of all partners (including the National Industrial Investment Fund). The partnership may extend the valid duration up to two times, with each extension not exceeding one year (the extension period may apply to the investment period and the exit period)

Implementation of
partnership affairs:

The general partner acts as executive partner to implement partnership affairs.

Management fees:

As consideration for the daily operation and investment management services provided by the fund manager to the Fund, all parties have agreed that the management fees shall be paid by the Fund to CNNC Fund in accordance with the following arrangements:

- (1) During the investment period (including any extension of the investment period), the annual management fee shall be 1.8% of the total paid-in capital contribution amount;
- (2) From the day after the expiry of the investment period and ends on the expiry date of the valid duration (excluding any extension of the exit period), the annual management fee shall be 1.5% of the total investment principal amount of projects that have not yet been exited;
- (3) No management fee shall be charged during any extension of the exit period or during the liquidation period.

Distribution:

(I) Cash distribution

1. Distribution of cash income received from investment projects shall be carried out according to the following order:
 - (1) Return of capital contribution to each partner.
 - (2) If remaining balance exists, the amount will be distributed as hurdle return to each partner (simple interest at 8%).

LETTER FROM THE BOARD

- (3) The excess profit will be shared on prorata basis. If remaining balance exists, 20% will be distributed to the general partner (the “**Excess Return**”), and 80% will be distributed to each limited partner in accordance with the relative ratio of the paid-in capital contribution amount by each limited partner.

2. Timing for distribution of cash income:

In principle, no later than 90 days after the Fund receives the relevant proceeds.

3. Upon expiry or termination and liquidation of the Fund, all investment projects shall be calculated on an aggregate basis, and a final consolidated calculation shall be conducted in accordance with the above distribution principles. If the excess profit actually paid to the general partner exceeds the amount of excess profit it is entitled to receive as calculated based on the above distribution principles after aggregating all investment projects, the general partner shall return the excess amount to the Fund, or such excess amount shall be deducted from the liquidation distribution amount payable to the general partner, and shall be distributed among the partners entitled to receive such distributions in accordance with the above distribution principles. Notwithstanding the foregoing, the general partner’s aggregate clawback obligation shall in no event exceed the amount of excess profit actually received by the general partner, net of any taxes paid or payable thereon.

- (II) Non-cash distribution

Before completion of the liquidation of the partnership, the executive partner shall make its reasonable endeavours to realize the investments of the partnership and avoid making non-cash distribution. However, if the investments cannot be realised or if, in the opinion of the executive partner, non-cash distribution would better serve the interests of all partners, such distribution shall be made in non-cash form upon unanimous consent of all partners.

LETTER FROM THE BOARD

Except for assets with a readily ascertainable market price, the value of all assets distributed in non-cash form pursuant to the above arrangements shall be determined by reference to the valuation prepared by a professional valuer being an Independent Third Party, designated by the executive partner.

The proportion, method and other arrangements for non-cash distributions shall be governed by the provisions applicable to cash distributions.

Management and
decision-making

CNNC Fund, as the executive partner and fund manager, is responsible for the daily operation and investment management of the Fund.

The Investment Committee shall be established under the Fund to consider and decide on investment matters relating to investment projects, material post-investment management matters and exit matters.

The Investment Committee shall comprise five (5) members. The National Industrial Investment Fund shall be entitled to recommend one (1) member, while the remaining four (4) members shall be recommended by CNNC and its affiliated enterprises. CNNC Fund shall, after conducting a comprehensive assessment of the candidates so recommended, appoint the members of the Investment Committee.

Each member of the Investment Committee shall have one vote. Resolutions of the Investment Committee shall be passed only upon the affirmative votes of no less than four-fifths (4/5) of all members of the Investment Committee. Each member of the Investment Committee shall exercise his or her independent judgment and cast the vote in his or her individual capacity when participating in the decision-making process of the Investment Committee.

LETTER FROM THE BOARD

CNNC and its affiliated enterprises and the National Industrial Investment Fund will recommend suitable candidates for appointment as members of the Investment Committee having regard to the characteristics of the Fund and the requirements of their respective internal management policies. Based on such recommendations, CNNC Fund will conduct a comprehensive assessment of the candidates, taking into account, among other things, their experience in investment management and nuclear technology application industry, professional qualification, educational background and ability to perform their duties. CNNC Fund will appoint as members of the Investment Committee those recommended candidates whom it considers suitable and competent following such assessment.

If the Fund's aggregate committed capital contributions to a single investment portfolio exceed 20% of the total capital contributions committed to the Fund, the unanimous consent of the partners' meeting shall be required.

Following the Fund's investment, the executive partner shall conduct ongoing monitoring on the relevant investment portfolio.

Investment Committee
observers:

The Company, the National Industrial Investment Fund, Zhejiang Province Entrepreneurship Guide Fund and Jiaxing Changchuang Industrial Investment shall each be entitled to appoint one observer. Observers may attend meetings of the Investment Committee but shall not participate in the Investment Committee's decision-making. They shall, however, be entitled to monitor compliance in relation to meeting notices, the materials submitted to the Investment Committee for decision-making, the investment decision-making procedures and other related matters.

Governing law:

The Partnership Agreement shall be governed by the laws of the PRC.

Dispute resolution:

Any dispute shall be submitted to the Beijing Arbitration Commission by the parties for arbitration in Beijing in accordance with the arbitration rules of the Commission.

The terms of the Partnership Agreement are determined after arm's length negotiations among the parties.

LETTER FROM THE BOARD

III. Core Management Team of the Fund Manager

As the fund manager, CNNC Fund will establish a management team comprising professionals with diverse backgrounds in the nuclear industry, equity investment, fund management, finance, legal affairs and capital markets. The core team members possess extensive experience in areas including investment in nuclear technology application-related industries, fund raising and establishment, project screening and due diligence, post-investment management and investment exits. The core management team members of CNNC Fund have, on average, more than 10 years of experience in the investment management sector.

Details of certain members of the core management team are set out below:

Tu Qiang (涂强) has led the management and operation of a number of funds, including CNNC (Zhejiang) Emerging Industries Equity Investment Fund (Limited Partnership) (中核(浙江)新興產業股權投資基金(有限合夥)), Beijing Tongfu Innovation Industrial Investment Fund Partnership (Limited Partnership) (北京同福創新產業投資基金合夥企業(有限合夥)), Ronghe Industrial Development Fund (Haiyan) Partnership (Limited Partnership) (融核產業發展基金(海鹽)合夥企業(有限合夥)) and Beijing Jianyuan Xuhe Equity Investment Fund Partnership (Limited Partnership) (北京建源旭核股權投資基金合夥企業(有限合夥)). Tu Qiang has extensive experience in industry research, project due diligence, capital operations and the fund raising, establishment and operation of private equity funds, and has participated in a number of major asset restructurings of listed companies, initial public offerings and projects involving the National Equities Exchange and Quotations (the “NEEQ”).

Zhu Li (朱莉) has more than 20 years of experience in capital operations in the nuclear industry and has been extensively involved in and taken a leading role in the initial public offering of a large state-owned enterprise on a main board and a number of equity investments in the nuclear industry. Zhu Li has overall responsibility for the operational management, project investment, post-investment management and project exits of the Yiheng Fund, and has accumulated extensive experience across the full fund management lifecycle. During Zhu Li’s management tenure, the distributions to paid-in capital (DPI) of Beijing Tongfang Yiheng Venture Capital Centre (Limited Partnership) (北京同方以衡創業投資中心(有限合夥)) increased rapidly.

Hao Bonan (郝伯男) holds legal professional and securities practitioner qualifications and has more than 12 years of experience in equity investment, with experience in managing various types of funds and in entrepreneurship in the healthcare sector. Hao Bonan has led investments in 12 projects in the nuclear technology application sector, with exits from a number of invested projects achieved through initial public offerings, mergers and acquisitions and equity transfers, and has accumulated extensive investment and fund operation experience in the nuclear technology application sector.

Liu Heng (劉珩) has extensive experience in fund management, equity management and capital operations. The projects in which Liu Heng has participated in management include 15 investments at Series A or earlier stages. Liu Heng has also invested in and supported eight

LETTER FROM THE BOARD

enterprises specialising in niche sectors with specialised expertise, refined operations, distinctive products and innovative capabilities (專精特新企業), two pre-IPO enterprises and one NEEQ-listed enterprise, and has led exits from four projects.

Wang Huan (王煥) has nearly 10 years of experience in equity investment. Among the projects in which Wang Huan has participated in investment and management, four investee companies have completed listings or formally submitted listing applications. Wang Huan's investment research covers innovative drugs (including radiopharmaceuticals), medical devices (including nuclear medical equipment), medical services, genetic testing, in vitro diagnostics, nuclear security and protection, and nuclear instruments and meters.

IV. Reasons and Benefits for Entering into the Partnership Agreement

The Fund has clearly defined investment scope and focuses on the nuclear technology application sector, including the production and preparation of isotopes, nuclear medical equipment and innovative drugs, industrial irradiation and inspection, security inspection and protection, as well as relevant applications of nuclear technology in the industrial, agricultural, medical, environmental protection and safety fields, together with key upstream and downstream links. The aforementioned investment directions are consistent with the Company's existing business layout and its long-term strategic development direction. As a leading enterprise in the nuclear technology application field in China, the Company intends to leverage the investment deployment of the Fund across the niche segments of the nuclear technology application industry to create the synergistic effect of the "fund + industry" model. This will enable the Company to indirectly participate in the innovation and incubation of cutting-edge technologies, thereby reducing the cost of trial and error in independent research and development. Through the fund, in addition to obtaining financial returns, the Company may secure preferential access to project cooperation rights, results commercialization rights and even strategic merger and acquisition opportunities, and rapidly transform external innovative achievements into new growth drivers for its own business. Leveraging the fund's industry events, project cooperation and other platforms, the Company may strengthen its exchanges and cooperation with peers and upstream and downstream enterprises along the industry chain, expand the scope for business cooperation, and empower its long-term development.

Pursuant to the currently applicable state-owned capital management system, if the Company makes direct investments, such investments would, in principle, be required to fall within the scope of the Company's principal business. In addition, from the formation of an investment intention, project initiation to the finalisation of the investment decision, the Company is required to undergo relatively complex internal decision-making and external approval procedures, with the overall process generally taking approximately 8 to 12 months. Therefore, if the Company conducts investments primarily for the purpose of obtaining investment returns, the direct investment approach would entail relatively higher procedural and time costs. In contrast, through participation in the Fund, the Company's investment capital is deployed by the Fund in a unified manner for project screening, investment decision-making and investment implementation, which shall be conducted pursuant to the

LETTER FROM THE BOARD

established investment strategy stipulated in the Partnership Agreement and under the decision-making and management mechanism of the meeting of all the partners of the Fund, the Investment Committee and the fund manager. Based on the past experience of similar funds, investments made through a fund generally take an average of approximately 3 to 4 months from project initiation to the completion of the investment decision. Accordingly, participation in the Fund helps to significantly reduce the procedural and time costs in the investment decision-making process and improve the efficiency of capital allocation and utilisation of the Company.

As to the risks for entering into the Partnership Agreement, the Company makes a relatively substantial investment in the Fund, with investment capital mainly to be recovered through exits from projects invested by the Fund; given the Fund's four-year investment period and four-year exit period, with project exits concentrated in the latter part of the exit period, the Company's investment may entail a lengthy capital recovery cycle, which may impair capital utilisation efficiency and give rise to the risk of long-term capital tie-up. In addition, the nuclear technology application sector features long research-and-development and commercialisation cycles, slow market cultivation and high susceptibility to policies and standards, and when compounded by technological iteration, cost volatility, insufficient capacity roll-out and mismatches between the Fund's term and expected project exits, there exists a risk that investment returns may fall short of expectations.

In assessing the Partnership Agreement, the Directors have considered, among other things:

- (a) the close alignment between the Fund's exclusive focus on the nuclear technology application industry and the Group's existing businesses and long-term development strategy;
- (b) the potential financial returns and strategic benefits;
- (c) the CNNC Fund's established experience and project sourcing capabilities in the relevant industry;
- (d) the benefits of obtaining diversified exposure to projects across different sub-sectors and stages of development through a professionally managed investment platform, as compared with the Group independently sourcing and managing a broad portfolio of minority investments;
- (e) the investment restrictions, diversification measures, staged capital contribution mechanism, reporting arrangements and other investor protection mechanisms under the Partnership Agreement; and
- (f) the risks associated with the investment.

LETTER FROM THE BOARD

The Directors have also considered the amount of the Company's capital commitment relative to the Fund's total committed capital, as well as the Group's existing cash resources, liquidity position and anticipated capital expenditure requirements, and are of the view that the capital commitment will not have a material adverse impact on the Group's operations or financial position. Having balanced the benefits and risks and made all reasonable enquiries, the Directors are of the view that the Company's participation in the Fund represents a commercially reasonable means of obtaining financial and strategic exposure to investment opportunities in the nuclear technology application industry, and that the terms of the transaction are fair and reasonable and the transaction is in the interests of the Company and its shareholders as a whole.

In particular, in respect of the management fee and Excess Return payable to CNNC Fund in its capacity as the general partner and fund manager of the Fund, having made reasonable enquiries and having given due consideration to the relevant circumstances, the Directors consider that the management fee and Excess Return rates under the Partnership Agreement are comparable to or more favourable than the prevailing market rates (for example, the management fee payable by Tongfu Innovation Industrial Investment Fund Partnership (Limited Partnership), in which the Company is a limited partner, is 1.6% per annum, calculated based on the aggregate paid-in capital contributions of the limited partners throughout the term of the fund, while its Excess Return rate is the same as that of the Fund (i.e. 20% of the excess profit)). Accordingly, the Directors consider that the management fee and Excess Return rates under the Partnership Agreement are fair and reasonable and do not confer any undue benefit on any connected person.

V. Directors Abstained from Voting on the Board Resolution

Among the Directors attending the Board meeting, the connected Directors, namely Mr. Xiao Yafei, Ms. Huo Yingying, Mr. Chen Zan, Mr. Ding Jianmin and Mr. Zhang Guoliang, were regarded as having a material interest in the Partnership Agreement by virtue of their employment with CNNC and its associates and had therefore abstained from voting on the relevant Board resolution.

VI. General Information

The Company

Focusing on the two major industrial directions of nuclear healthcare and irradiation application, the Company is committed to providing integrated solutions for nuclear medicine and radiotherapy, as well as radiation technology promotion and application, forming a "6+N" industrial layout with six major businesses as the core, including nuclides, nuclear medicines, nuclear medical equipment, integrated solutions for nuclear medicine, radioactive source and application, and irradiation application.

LETTER FROM THE BOARD

CNNC

CNNC was a company established under the laws of the PRC on 29 June 1999, and is the controlling shareholder of the Company. The ultimate beneficial owner of CNNC is the State-owned Assets Supervision and Administration Commission of the State Council.

CNNC Capital

CNNC Capital (formerly known as China National Nuclear Industry Construction Corporation Capital Holdings Limited) was established in July 2016 with a registered capital of RMB7.38 billion. It is a wholly-owned subsidiary of China National Nuclear Corporation and a financial services and specialized capital operation platform. Its principal business activities include corporate management, management consulting, investment activities using proprietary funds, asset management services for investments made using proprietary funds and information consultancy services. CNNC Capital has developed a comprehensive industry-finance business cluster featuring synergies across investment, financial leasing, asset management, insurance and carbon asset management (投-租-理-險-碳), with business operations covering financial leasing, industrial funds, commercial factoring, insurance brokerage, captive insurance and carbon asset management. The ultimate beneficial owner of CNNC Capital is the State-owned Assets Supervision and Administration Commission of the State Council.

CNNC Fund

CNNC Fund (formerly known as CNNC Industrial Fund Management (Beijing) Co., Ltd.) was established on 4 July 2011 with a registered capital of RMB150 million. It is a wholly-owned subsidiary of China National Nuclear Corporation Capital Holdings Co., Ltd. and is a licensed private equity fund management institution. Its principal business activities include non-securities investment management, consultancy and project investment, with a primary focus on equity investments across the upstream and downstream segments of the nuclear industry, including nuclear healthcare, nuclear technology applications and nuclear power. The ultimate beneficial owner of CNNC Fund is the State-owned Assets Supervision and Administration Commission of the State Council.

As a private equity fund manager, CNNC Fund has long-term in-depth engagement in the nuclear technology application industry. As of 31 December 2025, CNNC Fund had successfully operated eight funds, with the paid-in size of funds under management amounting to RMB4,823 million. The funds managed by CNNC Fund include Beijing CIRC Innovation Industrial Investment Fund Partnership (Limited Partnership) (北京同輻創新產業投資基金合夥企業(有限合夥)), which principally invests in the nuclear technology application sector. As at 31 December 2025, the funds managed by CNNC Fund had invested in a number of representative projects in the nuclear technology application sector, including the Company, Xi'an CNNC Nuclear Instrument Co., Ltd. (西安中核核儀器股份有限公司), Beijing Xiantong International Pharmaceutical Technology Co., Ltd. (北京先通國際醫藥科技股份有限公司) and Shaanxi Imdetek Co., Ltd. (陝西迪泰克新材料有限公司). In 2024, CNNC Fund received the

LETTER FROM THE BOARD

“Excellent Management Team Award for State-owned Capital Funds” and the “Top 10 Excellent Investment Case Awards for State-owned Capital” from the Central SOE Investment Association; in 2024 and 2025, CNNC Fund was awarded the “Excellent Innovation Investment Case Award for State-owned Capital” by the Central SOE Investment Association for two consecutive years.

As of 31 December 2025, CNNC Fund had a total of 48 full-time employees, with educational or professional backgrounds covering nuclear physics, bioengineering, pharmaceuticals, finance, accounting and law, among other fields. Of these employees, 39 held postgraduate degrees or above, while nine held bachelor’s degrees. In addition, 46 employees held the requisite fund practitioner qualifications.

National Industrial Investment Fund

The National Industrial Investment Fund was established on 20 March 2025 with a registered capital of RMB59.6 billion. The National Industrial Investment Fund conducts equity investment, investment management and asset management business in the form of a private investment fund. There is no shareholder holding 30% or more of the equity interest in the National Industrial Investment Fund, and the single largest shareholder is the Ministry of Finance (holding approximately 21% of the shares).

Zhejiang Province Entrepreneurship Guide Fund

Zhejiang Province Entrepreneurship Guide Fund was established on 27 February 2009, with a registered capital of RMB5 billion. Focusing on the development of Zhejiang Province’s “315” Scientific and Technological Innovation System, future industries and other priority sectors, the company invests in key technological innovation projects through cooperation with market-oriented institutions, with a particular focus on supporting early-stage and small enterprises, providing patient capital, and investing in hard technology, innovation platforms and innovative talent, thereby facilitating the commercialisation of scientific and technological achievements and fostering the development of new quality productive forces in light of local conditions. Its ultimate beneficial owner is Zhejiang Innovation Investment Group Co., Ltd.(浙江省創新投資集團有限公司), a state-owned enterprise in Zhejiang Province.

Jiaxing Changchuang Industrial Investment

Jiaxing Changchuang Industrial Investment was established on 9 April 2026 as an industrial chain fund with a target fund size of RMB3 billion established by the Jiaxing Municipal Finance Bureau. Focusing on Jiaxing’s “135N” advanced manufacturing clusters, Jiaxing Changchuang Industrial Investment aims to accelerate the development of a modern industrial system and promote the extension, supplementation and strengthening of industrial chains. Jiaxing Changtong Venture Capital Co., Ltd. (嘉興長投創業投資有限公司) serves as the manager, executive partner and general partner of Jiaxing Changchuang Industrial Investment. Its ultimate beneficial owner is Jiaxing Yangtze River Delta Innovation Investment Group Co., Ltd. (嘉興長三角創新投資集團有限公司), a state-owned enterprise based in Jiaxing.

LETTER FROM THE BOARD

Haiyan County State-owned Assets Investment

Haiyan County State-owned Assets Investment was established on 23 June 2015 with a registered capital of RMB10 million. Guided by the operating philosophy of “market-orientation, specialisation and standardisation”, the company focuses on areas including industrial investment, capital operation, asset management and financial services, and is committed to supporting local industrial transformation and upgrading and the development of emerging industries through equity investments, fund cooperation and industrial guidance. Its ultimate beneficial owner is Haiyan County State-owned Industrial Investment Group Co., Ltd. (海鹽縣國有產業投資集團有限公司), a state-owned enterprise in Haiyan.

VII. Implications of the Listing Rules

As at the Latest Practicable Date, CNNC directly and indirectly held approximately 73.83% of the Company’s total issued share capital through CIAE, NPIC, CNNC Fund and CNNC 404, and is the controlling Shareholder and a connected person of the Company. CNNC Capital and CNNC Fund are wholly-owned subsidiaries of CNNC. Therefore, CNNC Capital and CNNC Fund are associates of CNNC and connected persons of the Company under Chapter 14A of the Listing Rules. Accordingly, the entering into of the Partnership Agreement and the transactions contemplated thereunder constitute connected transactions of the Company.

As one or more of the applicable percentage ratios of the transactions under the Partnership Agreement exceed 5% but are less than 25%, the transactions contemplated thereunder are subject to the reporting, announcement, annual review and independent shareholders’ approval requirements under Chapter 14A of the Listing Rules. The entering into of the Partnership Agreement and the transactions contemplated thereunder also constitute a discloseable transaction of the Company.

3. PROPOSED APPOINTMENT OF DIRECTOR

The Board resolved to propose the appointment of Mr. Li Penghui (“**Mr. Li**”) as an executive Director of the fourth session of the Board with the term commencing from the date of approval by the Shareholders at the EGM to the date on which the term of office of the fourth session of the Board expires. The above appointment is subject to the approval by the Shareholders at the EGM.

Background of Mr. Li

Mr. Li Penghui, aged 54, is currently the general manager of the Company. Before joining the Company, Mr. Li served as deputy general manager in CNNC Xiapu Nuclear Power Co., Ltd. (中核霞浦核電有限公司) from June 2015 to November 2021; and from November 2021 to July 2026, he served as chief engineer in the CIAE. Mr. Li graduated from Harbin Institute of Technology in August 1994 with a bachelor’s degree of engineering, and began working in August of the same year. Mr. Li possesses the professional title of senior engineer.

LETTER FROM THE BOARD

Mr. Li has long been deeply involved in the field of nuclear technology application and possesses extensive experience in project coordination and scientific research management, as well as comprehensive capabilities in major engineering construction, core technology development and the operation of enterprises and research institutes.

Mr. Li was involved throughout the design and construction of China's first experimental fast reactor. He was a core member of the project, and the achievements of the project won the Special Prize of the National Science and Technology Progress Award. Mr. Li led the breakthrough of key core technologies for the demonstration fast reactor, and took the lead in advancing the establishment of Huludao Non-Beijing Base of CIAE (原子能院葫蘆島京外基地), efficiently promoting the approval and implementation of research reactor and isotope application projects.

As at the Latest Practicable Date, save as disclosed, Mr. Li did not hold any other positions with the Company or other members of the Group, nor did he hold any other directorships in the last three years in public companies the securities of which are listed on any securities markets in Hong Kong or overseas.

As at the Latest Practicable Date, save as disclosed, Mr. Li did not have any relationships with any Directors, senior management, substantial Shareholders or controlling Shareholders of the Company, nor any interest in the shares of the Company within the meaning of Part XV of the Securities and Futures Ordinance.

Subject to approval by the Shareholders at the EGM, Mr. Li will enter into a service contract with the Company for a term from the date when his appointment is approved by the Shareholders at the EGM to the date on which the term of office of the fourth session of the Board expires, and he shall be eligible for re-election and re-appointment upon the expiry of his term of office. The remuneration of Mr. Li is determined by the Board after considering the recommendations of the remuneration and appraisal committee of the Board in accordance with its terms of reference and taking into account, among other things, his duties and responsibilities.

Save as disclosed, there are no other matters relating to the appointment of Mr. Li that need to be brought to the attention of the Shareholders, nor is there any information that needs to be disclosed pursuant to Rules 13.51(2)(h) to (v) of the Listing Rules.

LETTER FROM THE BOARD

4. PROPOSED INTERIM DIVIDEND

(a) Proposed Interim Dividend

An ordinary resolution will be proposed at the EGM to consider and, if thought fit, approve the declaration and payment of interim cash dividend of RMB0.0994 per Share (inclusive of tax) for the six months ended 30 June 2026 (the “**2026 Interim Dividend**”) to Shareholders whose names appear on the register of members of the Company on Friday, 30 October 2026, with a total cash dividend to be distributed of RMB31,795,565.06 (inclusive of tax). The 2026 Interim Dividend is expected to be declared and paid in RMB to holders of Domestic Shares and, whereas dividends payable to holders of H shares will be declared in RMB and payable in HK\$ before Friday, 18 December 2026. Exchange rate between RMB and HK\$ will be the arithmetic mean of the median of the exchange rates of HK\$ against RMB as quoted by the PBOC for the five business days preceding the date of the declaration of dividend (inclusive).

According to the “Enterprise Income Tax Law of the People’s Republic of China” and its implementing rules, which came into effect on 1 January 2008, and other relevant rules, the Company is required to withhold 10% enterprise income tax before distributing the proposed 2026 Interim Dividend to non-resident enterprise Shareholders whose names appear on the register of members of the Company. Any H Shares registered in the name of non-individual registered Shareholders, including but not limited to HKSCC Nominees Limited, other nominees, trustees or other groups and organizations, will be treated as being held by non-resident enterprise Shareholders and therefore will be subject to the withholding of enterprise income tax.

According to the letter titled the “Tax arrangements on dividends paid to Hong Kong residents by mainland companies” issued by the Stock Exchange to the issuers on 4 July 2011 and a circular (Guo Shui Han [2011] No. 348) issued by the State Administration of Taxation on 28 June 2011, and relevant laws and regulations, if individual holders of H Shares are residents of Hong Kong or Macau or countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of 10%, the Company will withhold and pay individual income tax at the rate of 10% on behalf of such Shareholders. If individual holders of H Shares are residents of countries that have entered into a tax treaty with the PRC stipulating a dividend tax rate of less than 10%, the Company will nonetheless withhold and pay individual income tax at the rate of 10% on behalf of such Shareholders. In such a case, if the relevant Shareholders would like a refund of the additional amount withheld, the Company will apply for the agreed preferential tax treatment provided that information required by the applicable tax treaty notice(s) is submitted to the Company’s H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited. If individual holders of H Shares are residents of countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of more than 10% but less than 20%, the Company will withhold and pay individual income tax at the actual tax rate stipulated in the relevant tax treaty. If individual holders of H Shares are residents of countries which have entered into a tax treaty with the PRC stipulating a dividend tax rate of 20%, or countries which have not entered into any tax treaty with the PRC, or under any other circumstances, the Company will withhold and pay individual income tax at the rate of 20% on behalf of such Shareholders.

LETTER FROM THE BOARD

The Company assumes no responsibility and will not entertain any claim arising from any delay in, or inaccurate determination of, the tax status or tax treatment of Shareholders or any dispute over tax(es) withheld. Shareholders are recommended to consult their tax advisers regarding the PRC, Hong Kong and other tax effects involved in their holding and disposal of H Shares.

(b) Closure of Register of Members

As disclosed in the 2026 Interim Results Announcement, for the purpose of determining the entitlement of the Shareholders to attend and vote at the EGM, the register of members of the Company has been closed from Tuesday, 22 September 2026 to Tuesday, 29 September 2026 (both dates inclusive). For the purpose of determining the entitlement of the 2026 Interim Dividend, the register of members of the Company will be closed from Tuesday, 27 October 2026 to Friday, 30 October 2026 (both dates inclusive). Shareholders whose names appear on the register of members of the Company on Tuesday, 29 September 2026 will be entitled to attend and vote at the EGM. Shareholders whose names appear on the register of members of the Company on Friday, 30 October 2026 will be entitled to receive the 2026 Interim Dividend.

For the purpose of being qualified as Shareholders to attend and vote at the EGM, Shareholders of the Company must lodge all transfers documents with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares) or the Company's registered office in No. 66 Changwa Middle Street, Haidian District, Beijing, China (for holders of Domestic Shares) for registration no later than 4:30 p.m. on Monday, 21 September 2026. For the purpose of being qualified as Shareholders to receive the 2026 Interim Dividend (subject to the approval by Shareholders at the EGM), Shareholders must lodge all transfers documents with the Company's H Share Registrar (see the address above) (for holders of H Shares) or the Company's registered office (see the address above) (for holders of Domestic Shares) for registration no later than 4:30 p.m. on Monday, 26 October 2026.

5. PROPOSED GRANT OF GENERAL MANDATE TO ISSUE SHARES

To ensure that flexibility and discretion are given to the Directors to issue new Shares when they consider appropriate, a special resolution will be proposed at the EGM to consider and, if thought fit, approve the grant of the general mandate to the Directors to issue, allot and deal with H Shares representing up to the limit of 20% of the total number of the Shares in issue as at the date of passing such resolution to grant the general mandate:

- (a) subject to paragraph (b) below and in accordance with the relevant requirements of the Listing Rules, the Articles and the relevant laws and regulations of the PRC, the exercise by the Board during the Relevant Period (as defined below) of all the powers of the Company to determine and implement specific issue plan, consider and approve the agreements relating to the issue of Shares, consider and approve all documents to be submitted to the relevant authorities and perform all necessary

LETTER FROM THE BOARD

procedures, approve the corresponding increase in the registered capital of the Company, make corresponding amendments to the Articles and complete relevant mandatory registration and filing procedures, and determine other issues relating to the issue of Shares;

- (b) for the purpose of such resolution, “Relevant Period” means the period from (and including) the date of passing of such resolution until whichever is the earlier of:
 - (1) the conclusion of the next annual general meeting of the Company following the passing of such relevant resolution at the EGM;
 - (2) the expiration of a 12-month period following the passing of such relevant resolution at the EGM; or
 - (3) the revocation or variation of the given authorisation under such relevant resolution by the passing of a special resolution at the general meeting of the Company; and
- (c) such general mandate to the Board to make or grant offer proposals, agreements or options to issue H Shares shall not extend beyond the Relevant Period, other than in the case of the making or granting of offer proposals, agreements or options by the Board during the Relevant Period which might require the performance or exercise of such powers after the close of the Relevant Period.

Based on the issued shares of the Company comprising 239,906,100 domestic shares and 79,968,800 H shares, an aggregate of 319,874,900 shares as at the Latest Practicable Date, and assuming that no further shares will be issued prior to the date of the forthcoming EGM, subject to the approval of the resolution in relation to the general mandate, the Company may allot, issue and deal with up to 63,974,980 H Shares (on the basis that the Company will not further issue Domestic Shares and/or H Shares before the EGM).

The Board hereby states that there are no present plans to issue any new shares under the general mandate.

6. EGM

The Company will convene the EGM at 10:00 a.m. on Wednesday, 21 October 2026 at Room 403, 4/F, No. 66 Changwa Middle Street, Haidian District, Beijing, China. Notice of the EGM is set out on pages EGM-1 to EGM-2 of this circular. The proxy form for the EGM is enclosed herewith.

Shareholders who intend to appoint a proxy to attend the EGM are requested to complete the relevant proxy form in accordance with the instructions printed thereon. The relevant proxy form shall be lodged with (in respect of holders of H Shares) the Company’s H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen’s Road East, Wanchai, Hong Kong, or (in respect of holders of Domestic Shares) the Company’s head office and principal place of business in the PRC at No. 66 Changwa Middle Street, Haidian District, Beijing, China, as soon as possible and in any event not less than 24 hours before the time appointed for the holding of the EGM or any adjourned

LETTER FROM THE BOARD

meeting thereof (as the case may be), respectively. Completion and return of the relevant proxy form will not prevent you from attending and voting in person at the EGM or any adjourned meeting thereof should you so wish.

As at the Latest Practicable Date, CNNC, directly and indirectly, holds approximately 73.83% of the Company's total issued share capital, and is the controlling Shareholder of the Company. CNNC and its associates, having material interests in the Partnership Agreement, will abstain from voting at the EGM on the resolution in respect of the Partnership Agreement and the transactions contemplated thereunder. To the best knowledge, information and belief of the Directors having made all reasonable enquiries, save as disclosed herein, no other Shareholder is required to abstain from voting at the EGM.

7. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules and article 68 of the Articles of Association, any vote of Shareholders at a general meeting must be taken by poll, except where the chairman of the meeting, in good faith, decides to allow a resolution which relates purely to a procedural or administrative matter to be voted on by a show of hands.

8. RECOMMENDATION

Your attention is drawn to:


- (i) the letter from the Independent Board Committee set out on pages 27 to 28 of this circular which contains the advice and recommendation of the Independent Board Committee on the Partnership Agreement and the transactions contemplated thereunder.
- (ii) the letter from the Independent Financial Adviser set out on pages 29 to 52 of this circular which contains its recommendations to the Independent Board Committee and the Independent Shareholders on the Partnership Agreement and the transactions contemplated thereunder.

The Board considers that all resolutions to be proposed at the EGM are in the interests of the Company and the Shareholders as a whole, and recommends the shareholders to vote in favour of all such resolutions.

Your attention is also drawn to the additional information set out in the appendices to this circular.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 29 September 2026



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1763)

29 September 2026

To Independent Shareholders

Dear Sir/Madam,

**CONNECTED TRANSACTION
AND
DISCLOSEABLE TRANSACTION**

We refer to the circular of the Company to the Shareholders dated 29 September 2026 (the “**Circular**”), of which this letter forms part. Terms defined in the Circular shall have the same meanings when used in this letter unless the context otherwise requires.

We have been appointed as members of the Independent Board Committee to advise you as to whether the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement is on normal commercial terms which are fair and reasonable, is being entered into in the ordinary and usual course of business of the Group, and is in the interests of the Company and the Shareholders as a whole.

Rainbow Capital has been appointed as the Independent Financial Adviser to you and us in relation to the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement. Details of its recommendation are set out in the Letter from Rainbow Capital on pages 29 to 52 of the Circular.

Your attention is also drawn to the Letter from the Board set out on pages 5 to 26 of the Circular and the additional information set out in the appendix to the Circular.

Having considered the opinion of the Independent Financial Adviser in relation to the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement, we consider that such terms are on normal commercial terms which are fair and reasonable, are being entered into in the ordinary and usual course of business of the Group, and are in the interests of the Company and the Shareholders as a whole.

LETTER FROM THE INDEPENDENT BOARD COMMITTEE

Accordingly, we recommend that you vote in favour of the ordinary resolutions set out in the notice of EGM to approve the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement.

Yours faithfully,
For and on behalf of the
Independent Board Committee

Mr. Poon Chiu Kwok

Ms. Chen Jingshan

Mr. Lu Chuang

Mr. An Rui

Independent non-executive Directors

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

The following is the full text of a letter of advice from Rainbow Capital, the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders, which has been prepared for the purpose of incorporation in this circular.

Rainbow Capital (HK) Limited

29 September 2026

To the Independent Board Committee and the Independent Shareholders

China Isotope & Radiation Corporation
No. 66 Changwa Middle Street
Haidian District
Beijing, the PRC

Dear Sir or Madam,

CONNECTED TRANSACTION AND DISCLOSEABLE TRANSACTION CNNC (ZHEJIANG) NUCLEAR TECHNOLOGY APPLICATION INDUSTRIAL INVESTMENT FUND PARTNERSHIP AGREEMENT

INTRODUCTION

We refer to our appointment as the Independent Financial Adviser to the Independent Board Committee and the Independent Shareholders in respect of the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement (the “**Fund Agreement**”), details of which are set out in the “Letter from the Board” (the “**Letter from the Board**”) contained in the circular of the Company dated 29 September 2026 (the “**Circular**”). This letter forms a part of the Circular. Unless the context otherwise requires, capitalized terms used in this letter shall have the same meanings as those defined in the Circular.

On 28 August 2026, the Board of the Company has approved the entering into of the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement among CNNC, CNNC Capital, CNNC Fund, National Industrial Investment Fund, Zhejiang Province Entrepreneurship Risk Investment Guide Fund Management Limited, Jiaxing Changchuang Industrial Investment Equity Investment Partnership (Limited Partnership), and Haiyan County State-owned Assets Investment Co., Ltd.

As at the Latest Practicable Date, CNNC directly and indirectly holds approximately 73.83% of the Company’s total issued share capital through CIAE, NPIC, CNNC Fund and CNNC 404, and is the controlling Shareholder and a connected person of the Company. CNNC Capital and CNNC Fund are wholly-owned subsidiaries of CNNC. Therefore, CNNC Capital and CNNC Fund are associates of CNNC and connected persons of the Company under Chapter 14A of the Listing Rules. Accordingly, the entering into of the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement and the transactions contemplated thereunder constitute connected transactions of the Company.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

As one or more of the applicable percentage ratios of the transactions under the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement exceed 5% but are less than 25%, the transactions contemplated thereunder are subject to the reporting, announcement, annual review and independent shareholders' approval requirements under Chapter 14A of the Listing Rules. The entering into of the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement and the transactions contemplated thereunder also constitute a discloseable transaction of the Company.

The Independent Board Committee, comprising all the independent non-executive Directors, has been formed to advise the Independent Shareholders on whether the Fund Agreement is on normal commercial terms which are fair and reasonable, is being entered into in the ordinary and usual course of business of the Group, and is in the interests of the Company and the Shareholders as a whole. We, Rainbow Capital, have been appointed as the Independent Financial Adviser to advise the Independent Board Committee and the Independent Shareholders in the same regard.

As at the Latest Practicable Date, we did not have any relationships or interests with the Group, or CNNC that could reasonably be regarded as relevant to our independence. We have acted as the independent financial adviser to the independent board committee and the independent shareholders of the Company in relation to (i) the revision of annual caps for continuing connected transactions, details of which are set out in the circular of the Company dated 24 October 2024; and (ii) the renewal of continuing connected transactions, details of which are set out in the circular of the Company dated 18 December 2025. Other than that, there was no engagement or connection between the Group or CNNC and us in the last two years. Apart from normal professional fees paid or payable to us in connection with this appointment as the Independent Financial Adviser, no other arrangements exist whereby we had received any fees or benefits from the Group or CNNC. Accordingly, we are independent from the Company pursuant to the requirement under Rule 13.84 of the Listing Rules and therefore we are qualified to give independent advice in respect of the Fund Agreement.

BASIS OF OUR OPINION

In formulating our opinion and advice, we have relied on (i) the information and facts contained or referred to in the Circular; (ii) the information supplied by the Group; (iii) the opinions expressed by and the representations of the Directors and the management of the Group; and (iv) our review of the relevant public information. We have assumed that all the information provided and representations and opinions expressed to us or contained or referred to in the Circular were true, accurate and complete in all respects as at the date thereof and may be relied upon. We have also assumed that all statements contained and representations made or referred to in the Circular are true at the time they were made and continue to be true as at the Latest Practicable Date and all such statements of belief, opinions and intentions of the Directors and the management of the Group and those as set out or referred to in the Circular

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

were reasonably made after due and careful enquiry. We have no reason to doubt the truth, accuracy and completeness of the information and representations provided to us by the Directors and the management of the Group.

We consider that we have reviewed sufficient information currently available and corroborated and substantiated any public information referred to in this letter to reach an informed view and to justify our reliance on the accuracy of the information contained in the Circular so as to provide a reasonable basis for our recommendation. We have not, however, carried out any independent verification of the information provided, representations made or opinion expressed by the Directors and the management of the Group, nor have we conducted any form of in-depth investigation into the business, affairs, operations, financial position or future prospects of the Company, CNNC or any of their respective substantial shareholders, subsidiaries or associates.

PRINCIPAL FACTORS AND REASONS CONSIDERED

In arriving at our opinion and recommendation on the terms of the Fund Agreement, we have taken into account the principal factors and reasons set out below:

1. Information of the Group and counterparties

(i) *The Group*

The Group is primarily engaged in the research, development, manufacturing and sale of nuclides, diagnostic and therapeutic radiopharmaceuticals and radioactive source products for medical and industrial applications, the provision of irradiation service for sterilization purpose, material modification and engineering, procurement and construction (EPC) service for the design, manufacturing and installation of irradiation facilities and the provision of nuclear medical equipment and construction service of nuclear medicine department to hospitals and other medical institutions.

Set out below is a summary of the consolidated financial information of the Group for the three years ended 31 December 2025 (“FY2023”, “FY2024” and “FY2025”, respectively) as extracted from the Company’s annual reports for FY2024 and FY2025:

(a) *Financial performance*

	FY2025	FY2024	FY2023
	<i>RMB’000</i>	<i>RMB’000</i>	<i>RMB’000</i>
Revenue	7,187,661	7,574,756	6,634,992
Gross profit	3,621,598	3,682,832	3,482,239
<i>Gross profit margin</i>	<i>50.4%</i>	<i>48.6%</i>	<i>52.5%</i>

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

	FY2025 <i>RMB'000</i>	FY2024 <i>RMB'000</i>	FY2023 <i>RMB'000</i>
Other income, gains and losses	112,430	77,518	240,928
Selling and distribution expenses	(1,449,247)	(1,623,621)	(1,768,368)
Administrative expenses	(879,811)	(704,520)	(635,914)
Research and development costs	(301,915)	(300,286)	(306,051)
Impairment losses on trade and other receivables	(44,469)	(45,541)	(71,236)
Finance costs	(71,014)	(48,423)	(36,142)
Share of profits less losses of associates	(13,099)	(14,088)	(14,303)
Share of profit of joint ventures	29,651	21,353	31,284
Profit before tax	1,004,124	1,045,224	922,437
Profit attributable to the Shareholders	327,425	406,645	370,967

FY2024 compared to FY2023

The Group's revenue increased by 14.2% from RMB6,635.0 million for FY2023 to RMB7,574.8 million for FY2024, which was mainly due to an increase in revenue from nuclear medical equipment and related services, radioactive source and other businesses segments.

The Group's gross profit increased by 5.8% from RMB3,482.2 million for FY2023 to RMB3,682.8 million for FY2024 and gross profit margin decreased from 52.5% for FY2023 to 48.6% for FY2024. The increase in gross profit and the decrease in gross profit margin were primarily due to the increase in the revenue of the nuclear medical equipment and related services and other businesses, which had a lower gross profit margin as compared to other segments.

The Group's profit attributable to the Shareholders amounted to RMB406.6 million for FY2024, representing an increase of 9.6% from RMB371.0 million for FY2023, which was mainly due to the increase in gross profit.

FY2025 compared to FY2024

The Group's revenue decreased by 5.1% from RMB7,574.8 million for FY2024 to RMB7,187.7 million for FY2025, which was mainly due to a decrease in revenue from nuclear medical equipment and related services and nuclear medicine business segments.

The Group's gross profit decreased by 1.7% from RMB3,682.8 million for FY2024 to RMB3,621.6 million for FY2025 and the Group's gross profit margin increased from 48.6% for FY2024 to 50.4% for FY2025. The increase in gross profit margin was mainly

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

due to the Company's strengthened cost control measures during the year, which resulted in quality and efficiency improvement, and the increased gross profit margin in both the nuclear medicines and radioactive source business segments.

The Group's administrative expenses increased by 24.9% from RMB704.5 million for FY2024 to RMB879.8 million for FY2025, which was mainly due to the additional tax and late payment penalties paid by the subsidiary, Zhonghe Headway, during this year.

The Group's selling and distribution expenses decreased by 10.7% from RMB1,623.6 million for FY2024 to RMB1,449.2 million for FY2025, which was mainly due to the Company's continuous improvement of sales model and sales policy.

The Group's profit attributable to the Shareholders amounted to RMB327.4 million, representing a decrease of 19.5% from RMB406.6 million for FY2025. Such decrease was primarily driven by the decline in revenue and the increase in administrative expenses, which was partially offset by the decrease in selling and distribution expenses.

(b) Financial position

	As at 31 December 2025 RMB'000	As at 31 December 2024 RMB'000
Non-current assets, including:	6,380,699	5,849,059
Property, plant and equipment	4,644,489	4,328,121
Current assets, including:	9,335,558	8,918,302
Inventories	1,347,153	787,185
Trade and bill receivables	4,883,904	4,922,128
Cash at bank and on hand	2,591,226	2,649,354
Current liabilities, including:	5,290,878	5,023,381
Bank loans	896,293	940,725
Trade payables	719,016	791,481
Accruals and other payables	3,493,400	3,097,491
Non-current liabilities, including:	2,291,913	1,999,385
Bank loans	1,247,338	1,049,474
Corporate bonds	499,538	499,287
Equity attributable to the Shareholders	5,226,765	5,005,301

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

The Group's net assets attributable to shareholders remained stable at RMB5,226.8 million as at 31 December 2025, compared to RMB5,005.3 million as at 31 December 2024. The Group's adjusted net gearing ratios, being net debt (interest-bearing debt plus unaccrued proposed dividends) divided by adjusted equity (total equity of the Company less unaccrued proposed dividends), were 34.9% and 34.7% as at 31 December 2024 and 31 December 2025, respectively. The Group's quick ratios (total current assets, excluding inventories, divided by total current liabilities as of the same date) were 1.6 times and 1.5 times as at 31 December 2024 and 31 December 2025, respectively.

(ii) Other parties

CNNC

CNNC was a company established under the laws of the PRC on 29 June 1999, and is the controlling shareholder of the Company. The ultimate beneficial owner of CNNC is the State-owned Assets Supervision and Administration Commission of the State Council.

CNNC Capital

CNNC Capital (formerly known as China National Nuclear Industry Construction Corporation Capital Holdings Limited) was established in July 2016 with a registered capital of RMB7.38 billion. It is a wholly-owned subsidiary of China National Nuclear Corporation and a financial services and specialized capital operation platform. Its principal business activities include corporate management, management consulting, investment activities using proprietary funds, asset management services for investments made using proprietary funds and information consultancy services. CNNC Capital has developed a comprehensive industry-finance business cluster featuring synergies across investment, financial leasing, asset management, insurance and carbon asset management (投-租-理-險-碳), with business operations covering financial leasing, industrial funds, commercial factoring, insurance brokerage, captive insurance and carbon asset management. The ultimate beneficial owner of CNNC Capital is the State-owned Assets Supervision and Administration Commission of the State Council.

CNNC Fund

CNNC Fund (formerly known as CNNC Industrial Fund Management (Beijing) Co., Ltd.) was established on 4 July 2011 with a registered capital of RMB150 million. It is a wholly-owned subsidiary of China National Nuclear Corporation Capital Holdings Co., Ltd. and is a licensed private equity fund management institution. Its principal business activities include non-securities investment management, consultancy and project investment, with a primary focus on equity investments across the upstream and

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

downstream segments of the nuclear industry, including nuclear healthcare, nuclear technology applications and nuclear power. The ultimate beneficial owner of CNNC Fund is the State-owned Assets Supervision and Administration Commission of the State Council.

In assessing CNNC Fund's capability of acting as the general partner of the proposed fund, we have obtained and reviewed its qualifications and experience in managing funds and investments within the nuclear technology application sector. Based on our search on the website of the Asset Management Association of China, CNNC Fund was incorporated in 2011 and registered as a fund manager in 2015, with a registered capital of RMB150 million and total assets under management exceeding RMB10 billion. As at the Latest Practicable Date, CNNC Fund managed eight funds, seven of which were invested in the nuclear industry chain, nuclear technology applications, and uranium resources. Save for its investment in the Company in 2017 and its investments in private companies, CNNC Fund has participated in the investments of five companies that are either listed or have submitted/propose to submit listing applications, including Jiangxi Rimag Group Co., Ltd., Beijing Sinotau International Pharmaceutical Technology Co., Ltd., Chengdu Novel Medical Equipment Co., Ltd., Chengdu New Radiomedicine Technology Co., Ltd., and Boya Advanced Materials Co., Ltd. We have reviewed the public information of these companies and noted that they are primarily engaged in nuclear medical equipment and upstream materials, radiopharmaceuticals, and the production and preparation of isotope. Therefore, we consider that CNNC Fund possesses the appropriate qualifications and experience to manage the proposed fund.

National Industrial Investment Fund

The National Industrial Investment Fund was established on 20 March 2025 with a registered capital of RMB59.6 billion. The National Industrial Investment Fund conducts equity investment, investment management and asset management business in the form of a private investment fund. There is no shareholder holding 30% or more of the equity interest in the National Industrial Investment Fund, and the single largest shareholder is the Ministry of Finance (holding approximately 21% of the shares).

Zhejiang Province Entrepreneurship Guide Fund

Zhejiang Province Entrepreneurship Guide Fund was established on 27 February 2009, with a registered capital of RMB5 billion. Focusing on the development of Zhejiang Province's "315" Scientific and Technological Innovation System, future industries and other priority sectors, the company invests in key technological innovation projects through cooperation with market-oriented institutions, with a particular focus on supporting early-stage and small enterprises, providing patient capital, and investing in hard technology, innovation platforms and innovative talent, thereby facilitating the commercialisation of scientific and technological achievements and fostering the

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

development of new quality productive forces in light of local conditions. Its ultimate beneficial owner is Zhejiang Innovation Investment Group Co., Ltd. (浙江省創新投資集團有限公司), a state-owned enterprise in Zhejiang Province.

Jiaxing Changchuang Industrial Investment

Jiaxing Changchuang Industrial Investment was established on 9 April 2026 as an industrial chain fund with a target fund size of RMB3 billion established by the Jiaxing Municipal Finance Bureau. Focusing on Jiaxing's "135N" advanced manufacturing clusters, Jiaxing Changchuang Industrial Investment aims to accelerate the development of a modern industrial system and promote the extension, supplementation and strengthening of industrial chains. Jiaxing Changtong Venture Capital Co., Ltd. (嘉興長投創業投資有限公司) serves as the manager, executive partner and general partner of Jiaxing Changchuang Industrial Investment. Its ultimate beneficial owner is Jiaxing Yangtze River Delta Innovation Investment Group Co., Ltd. (嘉興長三角創新投資集團有限公司), a state-owned enterprise based in Jiaxing.

Haiyan County State-owned Assets Investment

Haiyan County State-owned Assets Investment was established on 23 June 2015 with a registered capital of RMB10 million. Guided by the operating philosophy of "market-orientation, specialisation and standardisation", the company focuses on areas including industrial investment, capital operation, asset management and financial services, and is committed to supporting local industrial transformation and upgrading and the development of emerging industries through equity investments, fund cooperation and industrial guidance. Its ultimate beneficial owner is Haiyan County State-owned Industrial Investment Group Co., Ltd. (海鹽縣國有產業投資集團有限公司), a state-owned enterprise in Haiyan.

2. Reasons for and benefits of entering into the Fund Agreement

As stated in the Letter from the Board, as a leading enterprise in the nuclear technology application field in China, the Company intends to leverage the investment deployment of the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund across the niche segments of the nuclear technology application industry to create the synergistic effect of the "fund + industry" model. This will enable the Company to indirectly participate in the innovation and incubation of cutting-edge technologies, thereby reducing the cost of trial and error in independent research and development. Through the fund, the Company may secure preferential access to project cooperation rights, results commercialization rights and even strategic merger and acquisition opportunities, and rapidly transform external innovative achievements into new growth drivers for its own business. Leveraging the fund's industry events, project cooperation and other platforms, the Company may strengthen its exchanges and cooperation with peers and upstream and downstream enterprises along the industry chain, expand the scope for business cooperation, and empower its long-term development.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

The proposed fund will align with the Three-Year Action Plan for High-Quality Development of the Nuclear Technology Application Industry (2024–2026), which was jointly issued by twelve authorities including the China Atomic Energy Authority. The scope of investments will focus primarily on (i) isotope production and preparation; (ii) nuclear medical and high-end equipment (comprising innovative radiopharmaceuticals, large-scale nuclear medical equipment, high-end irradiation devices, security inspection equipment, and radiation monitoring equipment); and (iii) key components and upstream materials. As advised by the management of the Company, when selecting investment targets, the proposed fund will adhere to the following parameters:

(i) Mature-stage projects: Priority will be given to high-quality listed companies and core enterprises specializing in nuclear technology applications under CNNC, CGN, and SPIC. Characteristics of such projects include: a proven business model currently in a rapid expansion phase; a complete team structure with stable core technical personnel; established customer bases and stable revenue streams, with positive or near-positive cash flows; and demonstrated competitive advantages or market share in niche sectors, with expected exit via IPO or M&A within three to five years.

(ii) Growth-stage projects: Investments will target highly market-driven sectors with clear growth potential, such as innovative radiopharmaceuticals, nuclear medical equipment, and irradiation applications. Characteristics of such projects include: core products that have entered clinical trials, pilot scale testing, or advanced stages, or have completed commercial verification, backed by proprietary intellectual property and technical barriers; a team possessing both R&D capability and market-oriented operational experience, with a stable core management team capable of integrating industrial resources; a clear path toward cash flow monetization; and a differentiated competitive edge in niche segments, with the potential to become sector leaders.

(iii) Seed-stage projects: Focus will be placed on commercializable technologies and cutting-edge research outcomes from national and state-owned research institutes—such as the China Institute of Atomic Energy, the Nuclear Power Institute of China, and the China Institute for Radiation Protection—that address critical strategic bottlenecks. Adopting a “patient capital” strategy, the fund will nurture technologies from the laboratory to the market, with a strong focus on original and disruptive technical innovations.

As stated in the Company’s annual report for FY2025, the Company serves as CNNC’s primary platform for nuclear technology applications, driving the growth of China’s broader nuclear technology sector. Guided by its strategic vision to build a stronger, larger, and better enterprise, the Company adheres to its dual strategy of “Industrialization and Globalization” to establish itself as a world-class provider of nuclear technology products and services. Aligned with its strategic objectives, the Company actively executes targeted M&A initiatives focused on securing upstream resources, strengthening core capabilities, and expanding downstream applications. In particular, the Group targets key areas such as radiopharmaceuticals, nuclear medical equipment, and irradiation applications, strategically acquiring assets based on market opportunities and long-term strategic alignment. For the year ended 31 December 2025, the Company operated five business segments, namely nuclear medicines, radioactive source

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

products, irradiation, nuclear medical equipment and related services and other businesses. The proposed scope of investments under the fund aligns with the Company's principal business activities. The establishment of the fund will enable the Company to actively participate in investments within relevant industries, systematically identify potential merger and acquisition opportunities, and enhance the return rate on its surplus capital. The Group had a cash balance of RMB2,591.2 million as at 31 December 2025 and a net cash inflow from operating activities of RMB538.3 million for FY2025. We consider that the capital contribution of RMB400 million by the Company under the Fund Agreement is not expected to have a material impact on the Group's financial position.

Based on the above, we consider that although the Fund Agreement is not entered into in the ordinary and usual course of business of the Group, it is in the interests of the Company and the Shareholders as a whole.

3. Principal terms of the Fund Agreement

Details of the terms of the Fund Agreement are set out in the Letter from the Board, which are summarized as follows:

Parties:	CNNC Fund (as the general partner) The Company (as the limited partner) CNNC (as the limited partner) CNNC Capital (as the limited partner) National Industrial Investment Fund (as the limited partner) Zhejiang Province Entrepreneurship Guide Fund (as the limited partner) Jiaxing Changchuang Industrial Investment (as the limited partner) Haiyan County State-owned Assets Investment (as the limited partner)
Amount of contribution:	The total capital contributions proposed to be committed by the partners are RMB3,000 million: CNNC Fund: RMB30 million (representing 1%); The Company: RMB400 million (representing 13.33%); National Industrial Investment Fund: RMB1,000 million (representing 33.33%); CNNC: RMB200 million (representing 6.67%); CNNC Capital: RMB170 million (representing 5.67%); Zhejiang Province Entrepreneurship Guide Fund: RMB400 million (representing 13.33%); Jiaxing Changchuang Industrial Investment: RMB400 million (representing 13.33%); Haiyan County State-owned Assets Investment: RMB400 million (representing 13.33%).

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

The contribution to CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund was determined by the Parties after arm's length negotiations with reference to the capital requirements of CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund. The Company intends to finance its capital contribution from the internal resources of the Group. The Company will not consolidate its financial statements with those of CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund.

Method of contribution:	All partners shall make contributions to CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund in RMB in cash in accordance with the notice of payment of contribution given by the executive partner to the limited partners. The date of receipt of funds specified in the notice of payment of the first contribution is the first closing date. All partners shall pay their subscribed capital contributions in full in two instalments during the investment period, with 40% and 60% of their respective subscribed capital contributions payable in the first and second instalments, respectively.
Purpose and scope of investment:	Engaging in investment activities, primarily through the acquisition, holding and disposal of interests in investment portfolios, to generate investment returns for the partners. CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund will invest in the application areas of nuclear technology, including the production and preparation of isotope, nuclear medical equipment and innovative drugs, industrial irradiation and inspection, security inspection and protection, as well as related applications and key upstream and downstream segments of nuclear technology in the industrial, agricultural, medical, environmental protection and security fields.
Term of operation:	Long-term, starting from the date of issuance of the first business licence of CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Valid duration, investment period, exit period and extension period:	The “valid duration” is eight (8) years from the first closing day. The “investment period” is four (4) years from the first closing day. The “exit period” commences on the day after the expiry of the investment period and ends on the expiry date of the valid duration. Subject to the operational needs of CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund (for example, where the investment period expires with the capital contributions remaining not fully invested, or where the exit period expires with the portfolio investments remaining not fully realized), the valid duration may be extended with the consent of partners holding more than two-thirds of the partnership interests (calculated based on the proportion of paid-in capital contributions) of all partners (including the National Industrial Investment Fund). The partnership may extend the valid duration up to two times, with each extension not exceeding one year (the extension period may apply to the investment period and the exit period).
Implementation of partnership affairs:	The general partner acts as executive partner to implement partnership affairs.
Management fees:	As consideration for the daily operation and investment management services provided by the fund manager to CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund, all parties have agreed that the management fees shall be paid by CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund to CNNC Fund in accordance with the following arrangements: (1) During the investment period (including any extension of the investment period), the annual management fee shall be 1.8% of the total paid-in capital contribution amount; (2) From the day after the expiry of the investment period and ends on the expiry date of the valid duration (excluding any extension of the exit period), the annual management fee shall be 1.5% of the total investment principal amount of projects that have not yet been exited; (3) No management fee shall be charged during any extension of the exit period or during the liquidation period.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Distribution: (I) Cash distribution

1. Distribution of cash income received from investment projects shall be carried out according to the following order:

(1) Return of capital contribution to each partner.

(2) If remaining balance exists, the amount will be distributed as hurdle return to each partner (simple interest at 8%).

(3) The excess profit will be shared on prorata basis. If remaining balance exists, 20% will be distributed to the general partner. 80% will be distributed to each limited partner in accordance with the relative ratio of the paid-in capital contribution amount by each limited partner.

2. Timing for distribution of cash income:

In principle, no later than 90 days after CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund receives the relevant proceeds.

3. Upon expiry or termination and liquidation of CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund, all investment projects shall be calculated on an aggregate basis, and a final consolidated calculation shall be conducted in accordance with the above distribution principles. If the excess profit actually paid to the general partner exceeds the amount of excess profit it is entitled to receive as calculated based on the above distribution principles after aggregating all investment projects, the general partner shall return the excess amount to CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund, or such excess amount shall be deducted from the liquidation distribution amount payable to the general partner, and shall be distributed among the partners entitled to receive such distributions in accordance with the above distribution principles. Notwithstanding the foregoing, the general partner's aggregate clawback obligation shall in no event exceed the amount of excess profit actually received by the general partner, net of any taxes paid or payable thereon.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

(II) Non-cash distribution

Before completion of the liquidation of the partnership, the executive partner shall make its reasonable endeavours to realize the investments of the partnership and avoid making non-cash distribution. However, if the investments cannot be realised or if, in the opinion of the executive partner, non-cash distribution would better serve the interests of all partners, such distribution shall be made in non-cash form upon unanimous consent of all partners.

Except for assets with a readily ascertainable market price, the value of all assets distributed in non-cash form pursuant to the above arrangements shall be determined by reference to the valuation prepared by a professional valuer being an Independent Third Party, designated by the executive partner.

The proportion, method and other arrangements for non-cash distributions shall be governed by the provisions applicable to cash distributions.

Investment
Committee
(the
investment
decision-
making body):

The Investment Committee shall be established under the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund to consider and decide on investment matters relating to investment projects, material post-investment management matters and exit matters.

The Investment Committee shall comprise five (5) members. The National Industrial Investment Fund shall be entitled to appoint one (1) member, while the remaining four (4) members shall be nominated by CNNC and its affiliated enterprises.

Each member of the Investment Committee shall have one vote. Resolutions of the Investment Committee shall be passed only upon the affirmative votes of no less than four-fifths (4/5) of all members of the Investment Committee.

Investment
Committee
observers:

The Company, the National Industrial Investment Fund, Zhejiang Province Entrepreneurship Guide Fund and Jiaxing Changchuang Industrial Investment shall each be entitled to appoint one observer. Observers may attend meetings of the Investment Committee but shall not participate in the Investment Committee's decision-making. They shall, however, be entitled to monitor compliance in relation to meeting notices, the materials submitted to the Investment Committee for decision-making, the investment decision-making procedures and other related matters.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

In assessing the fairness and reasonableness of the terms of the Fund Agreement, we have conducted a search on the website of the Stock Exchange and reviewed the terms of similar fund partnership agreements (the “**Comparable Agreements**”) entered into by companies listed on the Main Board of the Stock Exchange during the period from 1 February 2026 up to the date of approval of the Fund Agreement. We consider that such period of approximately six months is appropriate as it provides a sufficient and representative sample of Comparable Agreements to effectively reflect current market practices.

We have identified an exhaustive list of 7 Comparable Agreements. Although the financial positions of these listed companies and the background of the Comparable Agreements may differ from those of the Company, each of these transactions was entered into by the relevant companies to fulfill their investment requirements, which are consistent with the strategic objectives of the Company. Therefore, we consider the terms of the Comparable Agreements to be relevant and appropriate for reference.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

The table below sets out details of the Comparable Agreements:

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
Shanghai Pharmaceuticals Holding Co., Ltd. (2607)	18 July 2026	Three instalments: 40%, 30% and 30%	Term: 8 years Investment period: 4 years, which may be extended for one year at the discretion of the general partners	Investment period: 2.0% Exit period: 1.8%	(1) Return of capital contribution to limited partners. (2) Return of capital contribution to general partners. (3) If there is a surplus, allocate to the limited partners until its allocated dividends reach the return threshold (i.e., annualized simple interest of 8%). (4) If there is a surplus, allocate to the general partners until their allocated dividends reach 25% of the return threshold of such limited partner under item (3) above. (5) If there is a surplus, allocate between the general partners and limited partners in the proportion of 20:80.	The company as limited partner is entitled to appoint one member of investment decision-making committee and one member of investment advisory committee.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
Sunshine Lake Pharma Co., Ltd. (6887)	26 June 2026	Not disclosed	12 years	Not disclosed	Profits and losses of the fund shall be distributed and borne by partners in proportion to their actual capital contributions in the limited partnership fund.	Limited partners shall have the right to supervise the general and executive partner. The general and executive partner shall regularly report to the limited partners on the execution of the affairs as well as the business and financial status of the fund.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
China Communications Construction Company Limited (1800)	28 May 2026	Five instalments with each instalment representing 20%	8 years	Investment period: 1.26% Exit period: 0.56%	(1) Return of capital contribution to each partner. (2) If any surplus remains after the foregoing distribution, distribution shall be made to all partners in proportion to their respective partnership interest as at the distribution date, until the cumulative amount distributed to each partner achieves an annual performance benchmark return of 8% (simple interest).	The company as general partner is entitled to appoint one member of investment decision-making committee.
					(3) If any surplus still remains after the foregoing distributions, such amount shall be treated as excess returns and allocated among all partners as follows: 80% of the excess returns shall be distributed among the limited partners, and the remaining 20% shall be distributed among the general partners.	

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
Lee's Pharmaceutical Holdings Limited (950)	11 May 2026	Three instalments: 5%, 45% and 50%	Term: 8 years Investment period: 5 years Exit period: 3 years The term of the fund may be extended twice, with each time for another one year upon the proposal of the managing partner and with unanimous consent of all partners.	Investment period: 2.0%	Profit generated by the fund shall be first distributed to all the partners until each of them has received cumulative distributions equal to its cumulative contributed capital as of the relevant distribution date; thereafter, to all partners depending on the relevant apportionment ratio among the limited partners and the general partner, priority and return ratio as agreed in the limited partnership agreement.	The company as limited partner is entitled to appoint one observer for the investment committee.
Shandong Weigao Group Medical Polymer Company Limited (1066)	30 April 2026	Five instalments: 5%, 23.75%, 23.75%, 23.75% and 23.75%	Term: 8 years Investment period: 4 years Exit period: 4 years After the end of exit period, the duration of the fund may be extended twice, with each time for another one year.	Cumulative tiered rates Investment period: 2.2% – 1.0%	Not disclosed	The announcement did not specify whether limited partners could appoint members of the investment committee.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
Chengdu Expressway Co., Ltd. (1785)	20 April 2026	10% for the first instalment; Afterwards, the manager of the fund shall, subject to the actual operation and capital requirements of the fund, issue subsequent payment notices to all partners, who shall perform the payment obligations corresponding to their respective subscribed amount and at a consistent pace in principle	The term of the fund, as a limited partnership, shall be 20 years. The term of the fund as a private fund shall be until the date falling upon the tenth anniversary since the fund establishment date, which may be extended by up to two one-year periods. The term of investment of the fund shall span over a period from the fund establishment date until the seventh anniversary of the fund.	Investment period: 1% Exit period: 1%	(1) Return of all the paid-in capital of each partner as of the date of distribution in proportion to their respective paid-in capital as of such date; (2) Distribution of hurdle investment return (calculated at a simple annualised interest rate of 8%) to each partner in proportion to their respective paid-in capital as of the date of distribution; (3) In case of any surplus, 80% of such surplus amount shall be distributed to each partner in proportion to their respective paid-in capital as of the date of distribution, and 20% shall be distributed to the general partner of the fund as performance bonus.	The company as limited partner is entitled to appoint one member for the investment committee.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
APT Electronics Co., Ltd. (2551)	24 February 2026	Each partner shall make their paid-in capital contribution within 24 months after signing of the agreement, according to the requirements specified in the capital contribution payment notice to be issued by the fund manager.	Term: 7 years Investment period: 4 years Exit period: 3 years The exit period may be extended once for a term of two years.	Investment period: 1% Exit period: 0.1%	(1) Distributions shall be made to all partners in proportion to their respective paid-in capital contributions until the cumulative amount distributed to each partner equals its paid-in capital contribution to the fund; (2) Any remaining proceeds after the foregoing distribution shall be further distributed to all partners in proportion to their respective paid-in capital contributions until all partners have received an amount calculated based on their paid-in capital contribution to the fund at an annualized rate of return (simple interest) of 10% (inclusive); (3) Any remaining proceeds shall be distributed 5% to the fund manager and 95% to all partners in proportion to their respective paid-in capital contributions.	The company as limited partner is entitled to appoint one member for the investment committee.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Company name (stock code)	Date of announcement	Capital contribution	Duration	Management fee	Distribution	Supervision mechanism
The Company (1763)	28 August 2026	Two instalments: 40% and 60%	Term: 8 years	Investment period: 1.8%	(1) Return of capital contribution to each partner;	The company as limited partner is entitled to appoint one observer for the investment committee.
			Investment period: 4 years	Exit period: 1.5%	(2) If remaining balance exists, the amount will be distributed as hurdle return to each partner (simple interest at 8%);	
			Exit period: 4 years		(3) The excess profit will be shared on a pro rata basis. If remaining balance exists, 20% will be distributed to the general partner. 80% will be distributed to each limited partner.	
			The valid duration may be extended with the consent of partners holding more than two-thirds of the partnership interests of all partners. The partnership may extend the valid duration up to two times, with each extension not exceeding one year.			

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Capital Contribution

Capital contributions under all Comparable Agreements are to be made in instalments upon receipt of notice from the fund manager or the general partner. The specific proportion for each contribution varies among the Comparable Agreements. We consider that the initial capital contribution of 40% under the Fund Agreement is not materially higher than the initial contribution proportions observed in the Comparable Agreements.

Duration

Among the seven Comparable Agreements, five have a total fund term of seven to eight years, comprising an investment period of four to five years and an exit period of three to four years. Among the Comparable Agreements, (i) two provide for either a single two-year extension or two one-year extensions of the exit period; (ii) one provides for two one-year extensions of the investment period; (iii) one allows one-year extension for both the investment period and the exit period; and (iv) one provides for two one-year extensions applicable to either the investment period or the exit period. The duration structure (including two one-year extensions) under the Fund Agreement is generally in line with those of the Comparable Agreements.

Management Fee

The management fees under the Comparable Agreements range from 1.0% to 2.2% per annum during the investment period, and from 0.1% to 2.2% per annum during the exit period. The management fee payable under the Fund Agreement falls within the range of the Comparable Agreements.

Distribution

Among the seven Comparable Agreements, five adopt a standard distribution mechanism, being: (i) return of capital contributions to each partner; (ii) payment of hurdle return to each partner; and (iii) distribution of excess profits between the general partners and the limited partners. The Fund Agreement's distribution terms, comprising an 8% hurdle rate and an excess profit distribution ratio of 20:80 between the general partners and the limited partners, are generally consistent with the market practice reflected in the Comparable Agreements.

We noted that two of the Comparable Agreements stipulate that non-cash distributions shall be subject to the approval of the partners' meeting, without explicitly disclosing the specific circumstances under which a non-cash distribution may be proposed. Given that a non-cash distribution under the Fund Agreement will only be proposed if the relevant investments cannot be realized or if such distribution would better serve the interests of all partners, and that any non-cash distribution requires the unanimous consent of all partners, we consider that providing flexibility for non-cash distributions is fair and reasonable. This flexibility is particularly justified considering that investments in growth-stage or seed-stage companies generally require a longer holding period.

LETTER FROM THE INDEPENDENT FINANCIAL ADVISER

Supervision

Under the Fund Agreement, the Company, as one of the limited partners, is entitled to appoint one observer to the Investment Committee. Observer may attend Investment Committee meetings without voting rights or participation in decision-making, but is entitled to supervise compliance matters such as meeting notices, decision-making materials, and investment procedures. Among the seven Comparable Agreements, three allow the limited partner to appoint one member to the investment committee, while one allows the limited partner to appoint one observer to the investment committee. Although the Company is not entitled to appoint any member to the Investment Committee, the structure of appointing an observer solely in its capacity as a limited partner for oversight purposes is not uncommon in the market. We consider that the information, attendance, and inquiry rights granted to the Company's observer form a closed-loop supervision mechanism, which adequately enables the Company to effectively monitor the fund's investment operations and safeguards its capital security and investment returns as a limited partner. In addition, the National Industrial Investment Fund, as the largest limited partner and an independent third party, is entitled to appoint one member to the Investment Committee. This member can participate in investment decisions, thereby supervising the management and operation of the fund on behalf of other limited partners who are not associated with CNNC.

Based on our review set out above, we consider that the terms of the Fund Agreement are fair and reasonable.

OPINION AND RECOMMENDATION

Having taken into account the above principal factors and reasons, we consider that the Fund Agreement is on normal commercial terms which are fair and reasonable so far as the Independent Shareholders are concerned. Although the entering into of the Fund Agreement is not in the ordinary and usual course of business of the Group, we consider it to be in the interests of the Company and the Shareholders as a whole. We therefore advise the Independent Board Committee to recommend, and we ourselves recommend, the Independent Shareholders to vote in favor of the relevant resolutions to be proposed at the EGM to approve the Fund Agreement.

Yours faithfully,
For and on behalf of
Rainbow Capital (HK) Limited
Larry Choi
Managing Director

Mr. Larry Choi is a licensed person and a responsible officer of Rainbow Capital (HK) Limited registered with the Securities and Futures Commission to carry out type 1 (dealing in securities) and type 6 (advising on corporate finance) regulated activities under the SFO. He has over ten years of experience in the corporate finance industry.

1. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors having made all reasonable enquiries confirm that, to the best of their knowledge and belief, the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

2. DISCLOSURE OF INTEREST**Directors and chief executive of the Company**

As at the Latest Practicable Date, based on the information available to the Company and to the best knowledge of the Directors, none of the Directors or chief executive of the Company had any interest or short position in the Shares, underlying shares or debentures of the Company or any of its associated corporations (within the meaning of Part XV of the SFO) which was required to be notified to the Company and the Stock Exchange pursuant to Divisions 7 and 8 of Part XV of the SFO (including interests or short positions which they are taken or deemed to have under such provisions of the SFO), or which was required to be entered in the register kept by the Company pursuant to section 352 of the SFO, or which was required to be notified to the Company and the Stock Exchange pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers.

Competing interests

As at the Latest Practicable Date, none of the Directors or any of their respective associates was interested in any business (apart from the Group's business) which competed or was likely to compete directly or indirectly with the Group's business.

Service contracts

As at the Latest Practicable Date, there was no existing or proposed service contract (excluding contracts expiring or determinable by the Group within one year without payment of compensation (other than statutory compensation)) between any of the Directors and any member of the Group.

Interests in assets or contracts or arrangements significant to the Group

As at the Latest Practicable Date, none of the Directors had any direct or indirect interest in any asset which has been, since 31 December 2025 (being the date on which the latest published audited accounts of the Company were prepared), acquired or disposed of by or leased to any member of the Group, or is proposed to be acquired or disposed of by or leased to any member of the Group.

As at the Latest Practicable Date, none of the Directors was materially interested in any contract or arrangement subsisting at such date and being significant in relation to the business of the Group.

3. EXPERT'S QUALIFICATIONS AND CONSENTS

The following are the qualifications of the Independent Financial Adviser who has given its advice for inclusion in this circular:

Name	Qualifications
Rainbow Capital	A licensed corporation to conduct type 1 (dealing in securities) and type 6 (advising on corporate finance) regulated activities under the SFO

As at the Latest Practicable Date, the Independent Financial Adviser has given and has not withdrawn its written consent to the issue of this circular with the inclusion of its letter and reference to its name in the form and context as set out in this circular.

As at the Latest Practicable Date, the Independent Financial Adviser had no shareholding in any member of the Group or the right (whether legally enforceable or not) to subscribe for or to nominate persons to subscribe for securities in any member of the Group.

As at the Latest Practicable Date, the Independent Financial Adviser had no direct or indirect interest in any asset which has been, since 31 December 2025 (being the date to which the latest published audited accounts of the Company were made up), acquired or disposed of by or leased to any member of the Group, or is proposed to be acquired or disposed of by or leased to any member of the Group.

The letter and recommendation from Rainbow Capital is set out on pages 29 to 52 of this circular which are given for incorporation in this circular.


4. MATERIAL ADVERSE CHANGE

The Directors confirm that, as at the Latest Practicable Date, there had been no material adverse change in the financial or trading position of the Company since 31 December 2025, being the date to which the latest published audited accounts of the Company were made up.

5. DOCUMENTS ON DISPLAY


The following documents will be published on the website of the Stock Exchange (<https://www.hkexnews.hk>) and the website of the Company (<https://www.circ.com.cn/>) for at least 14 days from the date of this circular:

- (i) the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement;
- (ii) the letter from Rainbow Capital as set out on pages 29 to 52 of this circular;
- (iii) the written consent of Rainbow Capital referred to in the section headed “3. Expert’s Qualifications and Consents” above in this appendix.



NOTICE OF EXTRAORDINARY GENERAL MEETING

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



CHINA ISOTOPE & RADIATION CORPORATION

中國同輻股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 1763)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN by the board (the “**Board**”) of directors (the “**Directors**”) of China Isotope & Radiation Corporation (the “**Company**”) that the second extraordinary general meeting in 2026 of the Company (the “**EGM**”) will be held at 10:00 a.m. on Wednesday, 21 October 2026 at Room 403, 4/F, No. 66 Changwa Middle Street, Haidian District, Beijing, China by way of physical meeting to consider and, if thought fit, approve the following resolutions of the Company (unless otherwise specified, capitalised terms used in this notice shall have the same meanings as those defined in the circular of the Company dated on Tuesday, 29 September 2026 (the “**Circular**”)):

ORDINARY RESOLUTIONS

1. To consider and approve the CNNC (Zhejiang) Nuclear Technology Application Industrial Investment Fund Partnership Agreement and the transactions contemplated thereunder.
2. To consider and approve the proposed appointment of Mr. Li Penghui as an executive Director.
3. To consider and approve the proposed declaration and distribution of an interim dividend in the amount of RMB0.0994 per Share (inclusive of tax) for the six months ended 30 June 2026.

SPECIAL RESOLUTION

1. To consider and approve the proposed grant of general mandate to issue Shares.

By order of the Board
China Isotope & Radiation Corporation
Xiao Yafei
Chairman

Beijing, the PRC, 29 September 2026

NOTICE OF EXTRAORDINARY GENERAL MEETING

As at the date of this notice, the Board comprises Mr. Xiao Yafei and Ms. Huo Yingying as executive Directors; Mr. Chen Zan, Mr. Ding Jianmin, Mr. Zhang Guoliang and Ms. Chang Jinyu as non-executive Directors; and Mr. Poon Chiu Kwok, Ms. Chen Jingshan, Mr. Lu Chuang and Mr. An Rui as independent non-executive Directors.

Notes:

1. As disclosed in the 2026 Interim Results Announcement, the register of members of the Company has been closed from Tuesday, 22 September 2026 to Tuesday, 29 September 2026 (both dates inclusive). Shareholders whose names appear on the register of members of the Company on Tuesday, 29 September 2026 will be entitled to attend and vote at the EGM. For the purpose of being qualified as Shareholders to attend and vote at the EGM, Shareholders of the Company must lodge all transfer documents with the Company's H Share Registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong (for holders of H Shares) or the Company's registered office in No. 66 Changwa Middle Street, Haidian District, Beijing, China (for holders of Domestic Shares) for registration no later than 4:30 p.m. on Monday, 21 September 2026.
2. Each Shareholder who is entitled to attend and vote at the EGM may appoint one or more proxies in writing to attend and vote on his behalf. A proxy need not be a Shareholder.
3. The instrument appointing a proxy must be in writing by the appointor or his attorney duly authorised in writing, or if the appointor is a legal entity, either under seal or signed by a director or a duly authorised attorney. If that instrument is signed by an attorney of the appointor, the power of attorney authorising that attorney to sign or other authorisation document must be notarised.
4. To be valid, the proxy form and notarised power of attorney or other authorisation document must be delivered to (in respect of holders of H Shares) the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wanchai, Hong Kong, or (in respect of holders of Domestic Shares) the Company's head office and principal place of business in the PRC at No. 66 Changwa Middle Street, Haidian District, Beijing, China, as soon as possible but in any event no later than 24 hours before the time stipulated for holding the EGM (i.e. before 10:00 a.m. on Tuesday, 20 October 2026) or any adjourned meeting thereof. Completion and return of the proxy form will not preclude you from attending and voting at the EGM or at any adjourned meeting if you so wish. If a shareholder appoints more than one proxy, such proxies shall only exercise the right to vote by poll.
5. Shareholders or their proxies should produce proof of identity when attending the EGM. If a Shareholder is a legal entity, its legal representative or other person authorised by the board of directors or other governing body of such shareholder may attend the EGM by producing a notarially certified copy of the resolution of the board of directors or other governing body of such shareholder appointing such person to attend the EGM.
6. If Shares are held by joint holders, any such person may vote in person or by proxy at the EGM or at any adjourned meeting thereof, in respect of such Shares as if he/she was solely entitled thereto; whereas when two or more joint holders attend the EGM in person or by proxy(ies), only the person whose name appears first in the register of members in respect of such Shares shall alone be entitled to vote in respect thereof.
7. The EGM is expected to last for no more than half a day. Shareholders (or their proxies) attending the EGM in person are responsible for their own transportation and accommodation expenses.
8. Contact information of the Company

Address: No. 66 Changwa Middle Street, Haidian District, Beijing, China
(For the attention of the Joint Company Secretary)
Tel: +86 10 68511807
Fax: +86 10 68512374
Email: ir@circ.com.cn
9. References to dates and times in this notice are to Hong Kong dates and times.